Maternal infections with bacterial or viral agents during pregnancy are associated with an increased incidence of schizophrenia in the offspring at adulthood although little is known about the mechanism by which maternal infection might affect fetal neurodevelopment. Exposure of pregnant rodents to the bacterial endotoxin, lipopolysaccharide (LPS), results in behavioral deficits in the adult offspring that are relevant to schizophrenia. It is however unknown whether these effects are due to the direct action of the inflammatory stimulus on the developing fetus, or due to secondary immune mediators (cytokines) activated at maternal/ fetal sites. In this study we sought to elucidate the site of action of LPS, following a single intraperitoneal (i.p.) injection, in pregnant rats at gestation day 18. Animals received 5 lCi of iodinated LPS ( 125 I-LPS) and its distribution was assessed in maternal/fetal tissues (1-8 h). In addition, induction of the inflammatory cytokines, TNF-a, IL-1b and IL-6, was measured in maternal/fetal tissues following maternal LPS challenge (0.05 mg/kg, i.p.) (2-8 h).
Introduction
Several lines of evidence strongly indicate that schizophrenia is a disorder of neurodevelopmental origin. 1 Although genetic vulnerability plays a major role in the development of this disease, 2 it is thought that environmental factors also contribute to the etiology of the disorder. Epidemiological studies have demonstrated that prenatal exposure of pregnant women to environmental challenges, such as obstetric complications, 3 psychosocial stressors 4 and maternal infection, 5 all increase the risk of the offspring developing schizophrenia at adulthood. Maternal infection with viruses including influenza, 6 measles, 7 polio 8 and herpes simplex type 2, 9 and bacteria such as diphtheria and pneumonia, 5, 10 have been shown to be risk factors associated with the development of schizophrenia. In experimental studies using rodents at different stages during pregnancy, infection with human influenza virus, 11 the viral mimic polyinosinic: polycytidylic acid (poly I: C), [11] [12] [13] [14] or bacterial endotoxin (lipopolysaccharide (LPS)), 15, 16 resulted in behavioral changes relevant to schizophrenia in the adult offspring, such as decreased latent inhibition, 11, 13, 14 increased amphetamine-induced locomotion 12, 16 and disrupted prepulse inhibition (PPI) of acoustic startle. 15 The converging evidence from these studies suggests a causal relationship between viral or bacterial infections during pregnancy, and altered behavior in the adult offspring; however, the specific factors that mediate the effects of maternal infection on the developing fetal brain are unknown. Bacteria and viruses are potent activators of proinflammatory cytokines, such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b and IL-6, which are key effectors of the peripheral immune response 17 and the main mediators of brain orchestrated sickness responses following infection and inflammation. 18 In the periphery these cytokines act in a cascade-like fashion, which generally involves the sequential induction of TNF-a, IL-1b and IL-6. 19 Although the cytokinedependent inflammatory response is essential in resolving infection, abnormal changes in TNF-a, IL-1b and IL-6 levels during gestation, as a result of infection, may affect fetal brain development in utero. 20 Indeed, while cytokines have a key role in normal brain development, 21 they are implicated in the death and dysfunction of neurons following injury or chronic disease in the adult brain, 22 and are elevated in neurodevelopmental insults, such as hypoxia, also associated with an increased risk of schizophrenia. 23 Thus, cytokines are logical candidates to mediate the effects of maternal infection on the fetus; however, there have been contradictory reports of both increased and decreased expression of these mediators in the fetal brain following exposure of pregnant rats to bacterial LPS. 24, 25 Therefore, it remains unclear whether maternal LPS exposure during pregnancy results in altered cytokine expression in the fetal brain. Furthermore, none of the studies to date have explored whether LPS itself has direct actions on the fetal brain following LPS challenge of pregnant dams.
LPS signaling in the brain occurs through Toll-like receptor-4 (TLR4) 26, 27 and binding of LPS to this membrane receptor results in the activation of nuclear factor (NF)-kB 26 and subsequent transcription of genes encoding inflammatory mediators including TNF-a, IL-1b and IL-6. 28 TLR4 expression has been reported in the neonatal 29, 30 and adult rat brain, 31 and LPS can induce cytokine expression in glial and neuronal cultures prepared from human, murine and rat fetal brain; [32] [33] [34] [35] [36] however, it remains controversial whether transplacental transfer of LPS occurs in rodents in vivo. 37, 38 The aim of the present study therefore was to investigate the distribution and site of action of LPS (i.e. fetal, placental and/or maternal) in order to elucidate whether behavioral changes observed in the adult offspring of dams infected during pregnancy are mediated via the direct, or indirect, action of LPS on the fetal brain. To address this, pregnant rat dams were administered 5 mCi of radiolabeled LPS on day 18 (d18) of gestation and the distribution of labeled LPS assessed using (i) whole-body autoradiography and (ii) direct quantification of tissue levels of radioactivity. In addition, and in order to correlate tissue-specific changes in cytokine levels with the distribution of LPS, we measured changes in the expression of TNF-a, IL-1b and IL-6 in maternal/fetal tissues using species-specific immunoassays.
Materials and methods

Animals
Pregnant (d18) Sprague-Dawley rats (Charles River, Montreal, Canada), with an average body weight of 325.773.07 g, were used in all experiments. The animals were housed individually in a controlled environment at an ambient temperature of 21721C and a 12 h light/dark cycle (lights on from 0800 to 2000 h). Food and water were provided ad libitum. All procedures were performed in accordance with the guidelines established by the Canadian Council on Animal Care and were approved by the McGill University Animal Care Committee.
Radioiodination of LPS
LPS from Escherichia coli 0111:B4 (Lot 42k4120; L-2630, Sigma, Canada) was used in all experiments. LPS was radiolabeled with 125 I according to the method of Ulevitch. 39 Briefly, 1 mg of LPS was incubated with 50 mM p-OH-methylbenzimidate (Fluka, Germany) in 1 ml of 0.05 M borate buffer (pH 8.0) for 18 h at 371C. LPS coupled to p-OH-methylbenzimidate (1 ml) was then added to a vial containing 10 mCi of 125 I-Na (Perkin-Elmer, Canada) and the reaction initiated by adding 50 ml of chloramine T (2 mg/ml water). After 30 min at room temperature (RT), the reaction was terminated by adding 100 ml sodium metabisulfite (2 mg/ml water). Iodinated LPS was then separated from free 125 I on a Sephadex G-50 superfine column (Sigma, Canada) and eluted in 0.05 M sodium phosphate buffer (pH 7.4). It has been previously demonstrated that radioiodination of LPS using this method does not alter the biophysical or biological properties of LPS. I-LPS (5 mCi in 250 ml) and the distribution of the radiolabeled compound in maternal/fetal tissues was assessed qualitatively, using whole-body autoradiography and, quantitatively, by measurement of tissue levels of radioactivity using a gamma counter, over a time course after treatment. For whole-body autoradiography, pregnant rats were injected with 125 I-LPS and terminally anaesthetized 1, 2, 4 and 8 h (n ¼ 1/time point) after treatment (i.p. injection of 50 mg/kg ketamine, 5 mg/kg xylazine and 0.5 mg/kg acetaprazine/0.4 ml per animal). These animals were then frozen whole in isopentane and stored at À801C until cryo-sectioning. For analysis of tissue levels of radioactivity using the gamma counter, pregnant dams were injected with 125 I-LPS (n ¼ 5) or saline alone (250 ml; n ¼ 3), and deeply anaesthetized 2 h after treatment as previously described. Maternal trunk blood was collected by cardiac puncture, and maternal liver, kidney and brain collected, washed in sterile saline, weighed and then frozen at À801C until use. The placentas, fetal liver and fetal brain were harvested from six amniotic sacs per dam. Placental/liver/brain tissues were weighed and then stored at À801C. In addition, one fetus per dam was washed in sterile saline, frozen whole and stored at À801C until use.
Whole-body autoradiography
The frozen bodies of dams injected with 125 I-LPS were embedded in carboxymethylcellulose (sodium salt, #150560, ICN Biomedicals Inc., Canada) and sectioned in a cryo-microtome (LKB 450 MP) using a heavy-duty steel carbide-tipped knife (profile D) (Pharmacia, Germany). Whole-body sections (50 mm) were cut at the level of the spleen, kidney and spinal cord. These three levels were selected so that all major maternal organs, in addition to placentas, amniotic sacs and fetuses, were represented in the sections collected from each dam. The whole-body sections were then collected onto tape (Type 810, 3 M, Leica, Canada), freeze dried overnight (O/N) and then mounted on cardboard and apposed against Kodak BioMax MR photographic film (Amersham, Canada). They were exposed for 1 month and then developed in Kodak D-19 developer and rapid fixer. The amount of radioactivity in maternal blood, liver, kidney and brain, as well as the placenta and fetus, was then assessed in the three sections collected per dam using densitometry (MCID Elite version 6 Image Analysis System; Imaging Research Inc., Canada). The optical density of iodinated LPS detected in the tissue sections was calibrated using a 125 I-standard scale (Amersham, Canada) and is expressed as nCi/g tissue wet weight.
Tissue levels of 125 I-LPS measured by gamma counter Maternal/fetal tissues were placed in polypropylene low-density tubes (Sarstedt, Canada) and the amount of radioactivity measured using a gamma counter (Cobrat II Auto-Gamma, Packard, USA). Background levels, calculated from tissues harvested from dams treated with saline alone, were subtracted from those detected in tissues from dams treated with iodinated LPS. Results are expressed in counts per minute (c.p.m.) per mg tissue, or per ml plasma, respectively.
Measurement of cytokine induction in maternal/fetal tissues Pregnant dams were injected with LPS (0.05 mg/kg, i.p.) or saline (1 ml/kg), and killed by live decapitation 2, 4 and 8 h after treatment (n ¼ 5/time point). Protein expression of TNF-a, IL-1b and IL-6 was assessed in maternal plasma, placenta, fetal liver, fetal brain and fetal plasma using rat-specific enzymelinked immunosorbent assay (ELISA). This dose of LPS was selected because in preliminary studies it was found to induce a significant increase in both serum cytokines and maternal body temperature (i.e. fever) in cycling female rats, and was tolerated by d18 pregnant rat dams. Furthermore, we have previously reported that this dose induces behavioral deficits in the offspring of dams exposed to LPS during pregnancy. 16 Maternal trunk blood was collected into sterile tubes containing pyrogen-free heparin (10 U/ml). The blood samples were then centrifuged (5300 g, 10 min at 41C) and plasma collected and stored at À801C. Placentas, liver and brain from six fetuses per dam were collected and frozen at À801C until analysis of cytokine concentrations.
A separate group of dams were challenged with LPS (0.05 mg/kg, i.p.), or saline (n ¼ 12-13/group), and fetal trunk blood collected 4 h after treatment. The uterine horn was removed and placed on ice and the fetuses extracted from the amniotic sacs. These were then washed in sterile saline, decapitated and the trunk blood collected. Blood from all of the fetuses from a single dam was pooled in a sterile tube containing pyrogen-free heparin (10 U/ml). Fetal trunk blood was processed in the same way as maternal trunk blood, and the plasma stored at À801C until use. ELISA Placental, fetal liver and fetal brain tissues were homogenized with a hand-held sonicator (Model CP130PB-1, Cole-Parmer Instruments, USA) in a cocktail of protease inhibitors (100 mM amino-ncaproic acid, 10 mM disodium EDTA, 5 mM benzamidine and 0.2 mM AEBSF). The homogenates were then incubated on ice for 30 min and centrifuged at 14 000 g, for 10 min at 41C. The protein concentration of each supernatant was determined using a Bradford protein assay (Sigma, Canada) and the samples stored at À801C. Concentrations of the proinflammatory cytokines TNF-a, IL-1b and IL-6 were measured in maternal plasma, placenta, and fetal liver, brain and plasma, using a two-site, rat-specific ELISA (NIBSC, Potters Bar, UK) as described previously. 40 All samples and standards were assayed in duplicate. Intra-and interassay coefficients of variability were o7% for all assays and the detection limit for TNF-a, IL-1b and IL-6 was p31.25 pg/ml.
Statistical analysis
ELISA results were analyzed using two-way ANOVA and Bonferroni post-hoc tests. When statistical comparisons were made between two groups, an unpaired t-test was used. Probabilities of Po0.05 were considered significant.
Results
Distribution of 125
I-LPS in maternal/fetal tissues The tissue distribution of iodinated LPS was assessed in whole-body sections, over a time course (1-8 h) after the intraperitoneal injection of pregnant rat dams with 5 mCi of 125 I-LPS, using whole-body autoradiography (Figure 1 ). Iodinated LPS was observed in the body cavity, surrounding the maternal organs and amniotic sacs, 1 h after treatment ( Figure  1a) . 125 I-LPS was also detected in maternal blood, liver and kidney 1-8 h after treatment (Figure 1a-e) , and in the placenta 2-8 h after treatment (Figure 1b-e) . Levels of radiolabeled LPS in the maternal brain and fetus were below the limits of detection at all time points examined (Figure 1a-e) .
In order to quantify the amount of 125 I-LPS reaching maternal/fetal organs following injection of dams with 5 mCi of 125 I-LPS, tissue levels of radioactivity were measured using a gamma counter (2 h).
125 I-LPS was detected in maternal plasma (413 000 c.p.m./ml), liver, kidney and placenta (44 c.p.m./mg) 2 h after treatment (Table 1) . Low levels of radioactivity were detected in the maternal brain, fetal liver and fetal brain (o1 c.p.m./mg); however, these were minimal in comparison to the levels observed in maternal tissues such as kidney and liver (Table 1) .
LPS-dependent induction of cytokines in maternal/ fetal tissues
Maternal plasma. TNF-a, IL-1b and IL-6 concentrations were assayed in maternal plasma, 2, 4 and 8 h after endotoxin exposure. Minimal plasma levels of these cytokines were observed in saline-treated dams at all time points examined ( Figure 2 ). As expected, LPS resulted in a time-dependent induction of all three cytokines in maternal plasma (Figure 2 ). Significant increases in plasma TNF-a concentrations were observed 2 h after LPS treatment (Po0.01) (Figure 2a) , whereas plasma levels of IL-1b peaked 4 h after treatment (Po0.001) (Figure 2b ) versus saline alone. A significant increase in plasma IL-6 was observed 2 and 4 h after LPS versus saline alone (Po0.01 and 0.001 respectively) (Figure 2c ).
Placenta. Although TNF-a, IL-1b and IL-6 proteins were present in the placenta under basal conditions, maternal exposure to LPS induced a time-dependent increase in the expression of these inflammatory cytokines (Figure 3) . A significant increase (Po0.05) in the amount of TNF-a expressed in placental tissue was observed 2 h after treatment with LPS compared to saline alone (Figure 3a) . Similarly, placental levels of IL-1b increased significantly 4 (Po0.001) and 8 h (Po0.01) after LPS (Figure 3b ). In addition, a significant induction of IL-6 (Po0.05) was observed in the placenta 8 h after treatment with LPS versus saline alone (Figure 3c ).
Fetal liver and brain. Basal expression of all three cytokines tested was observed in the liver and brain of fetuses collected from mothers treated with saline alone. Treatment of pregnant dams with LPS did not increase the levels of these proteins in either tissue at any of the time points examined compared to saline alone (Table 2) . Furthermore, exposure of pregnant dams to LPS did not affect mRNA levels of TNF-a, IL1b or IL-6 in the fetal brain over the same time course (data not shown).
Fetal plasma. In a separate group of animals, fetal plasma cytokine levels were measured 4 h after treatment of the mothers with LPS (corresponds to the time of peak induction of IL-1b in maternal plasma and placenta). Fetuses from dams treated with LPS had significantly (Po0.05) increased plasma levels of IL-1b compared to fetuses from salinetreated control dams (Figure 4) . However, maternal LPS had no effect on TNF-a or IL-6 concentrations in the fetal plasma at this time point (data not shown). 
Discussion
In this study, we provide evidence to suggest that the altered behaviors observed in the offspring of dams treated with LPS 15, 16 are most likely due to the indirect action of LPS at maternal/placental sites rather than a direct action on the developing fetal brain.
125
I-LPS was detected in maternal tissues including blood, liver and kidney, as well as the placenta, 1-8 h after injection (Figure 1 and Table 1 ). No 125 I-LPS was observed in the maternal brain or fetus using wholebody autoradiography (Figure 1) . Although low levels of radioactivity were detected in these tissues using the gamma counter, they were minimal in comparison to the levels observed in maternal liver or kidney (Table 1) . This, and the lack of cytokine induction observed in both the fetal liver and brain ( Table 2 ), suggests that negligible amounts of LPS, insufficient to induce an inflammatory response, reach the fetus following maternal challenge with LPS. In agreement with these data, Goto et al. 37 reported that exposure of pregnant rats to LPS on d19 of pregnancy led to endotoxin-like activity in the maternal, but not fetal, plasma 2 h after treatment. It is therefore possible that the low levels of radioactivity we detected in the maternal brain and fetus could represent free 125 I. Taken together, these data suggest that significant transplacental transfer of LPS does not occur in the pregnant rat (d18) following maternal exposure to LPS, and that behavioral changes reported in the offspring of rat dams challenged with LPS 15,16 are therefore not due to the direct action of LPS on the fetal brain. Although Romero et al. 41 reported that bacterial LPS does not cross human chorioamniotic membranes in vitro, direct in vivo evidence indicating whether the human placenta forms the same type of barrier to LPS transfer to the fetus is lacking. However, the human and rat placentae do share some important structural similarities and are both of the hemochorial type; furthermore, they have comparable permeability to a range of hydrophilic compounds. 42, 43 LPS-dependent induction of the inflammatory proteins, TNF-a, IL-1b and IL-6, was observed in maternal plasma, 2-8 h after treatment of pregnant dams with LPS (0.05 mg/kg) (Figure 2 ). Although the relationship between maternal plasma cytokine levels and the subsequent development of behavioral abnormalities in human offspring has not been extensively investigated to date, one study in humans did demonstrate that increased plasma levels of TNF-a were observed in pregnancies in which offspring subsequently developed schizophrenia and other psychoses. 44 In addition, we observed a time-dependent upregulation of TNF-a, IL-1b and IL-6 in the placenta following maternal LPS (Figure 3) . This, and the observation of appreciable levels of 125 I-LPS in the placenta after maternal 125 I-LPS administration, suggests that LPS is acting directly on placental cells to induce the expression of these inflammatory mediators. What effect the upregulation of these cytokines may have on normal fetal development is still a question that is not wholly resolved; however, it is known that cytokines have an integral role in placental development and function during pregnancy, as well as modulating uterine contractions, membrane rupture and dilation of the cervix at parturition. 45 There is also evidence that inflammatory responses at the level of the placenta can lead to tissue damage, 46 which may result in reduced delivery of oxygen and nutrients to the developing fetus. 45, 47 In humans, hypoxic insult to the developing fetal brain is a risk factor implicated in the subsequent development of schizophrenia later in life; 48 furthermore, abnormal cytokine expression at the level of placenta has been implicated in premature birth, 49 fetal growth restriction 50, 51 and pre-eclampsia, 52 all of which are associated with increased incidence of schizophrenia in the adult offspring. 48 Thus, it is feasible that the altered behavior that we and others observed in the offspring of rat dams treated with LPS 15, 16 could be due to deficiencies in placental function resulting from inflammatory responses in this tissue rather than direct effects of LPS on fetal brain. Indeed, placental pathology has been linked to other neurodevelopmental disorders including cerebral palsy and mental retardation. 53 Although challenge of pregnant dams with the low dose of LPS used in this study induced significant increases in the expression of TNF-a, IL-1b and IL-6 proteins in both the maternal plasma ( Figure 2 ) and placenta ( Figure 3) , it had no effect on the level of these cytokines in the fetal brain at any time point examined (Table 2 ). Interestingly, two earlier studies did observe altered cytokine expression in the fetal brain following i.p. injection of pregnant rats with LPS. 24, 25 Cai et al. 24 reported increased expression of TNF-a and IL-1b mRNA in the fetal brain, 1 h after treatment of d18 pregnant rat dams with LPS (4 mg/ kg, i.p.). In contrast, Urakubo et al. 25 reported a decrease in TNF-a protein levels in the same tissue 2 h after challenge of d16 pregnant dams with LPS (2.5 mg/kg, i.p.), but no change in TNF-a or IL-1b protein levels 2 or 8 h after treatment of pregnant dams with a lower dose of LPS (0.5 mg/kg, i.p.). However, more recently Gayle et al. 54 also reported no change in the expression of TNF-a, IL-1b and IL-6, mRNA in the fetal brain following treatment of pregnant rats with LPS (0.1 mg/kg, i.p.) on d18 of pregnancy. In the two studies that reported altered cytokine expression in the fetal brain, high doses of LPS, 1 mg/kg and above, were used. In our laboratory, injecting pregnant dams with a high dose of LPS (1 mg/kg), albeit a different serotype, resulted in the death of fetuses 2 h after treatment. This raises the possibility that changes in cytokine levels observed in the fetal brain following exposure of pregnant dams to high doses of LPS could be the result of tissue necrosis.
Although maternal exposure to LPS did not affect the expression of TNF-a, IL-1b or IL-6 proteins in either the fetal liver or fetal brain (Table 2 ), significant increases in fetal plasma IL-1b were observed, 4 h after LPS (Figure 4 ). In the absence of appreciable transfer of LPS to the fetal compartment (Figure 1) , the increase in IL-1b levels detected in the fetal plasma is either due to transplacental transfer from the maternal blood or due to direct transfer from the placenta. In contrast, we failed to detect any increases in either TNF-a or IL-6 in the fetal plasma. This is most likely due to timing as opposed to any specific mechanisms favoring the transfer of IL-1b over the other two cytokines, since the time course of induction for each differs significantly in animals treated with LPS (i.e. placental TNF-a and IL-6 levels peaked at 2 and 8 h, respectively, while IL-1b peaked at 4 h). Increases in IL-1b concentrations, and possibly other cytokines, in the fetal circulation could influence fetal brain development directly, or indirectly, via the modulation of secondary mediators such as insulinlike growth hormone-1 (IGF-1), which was shown to be significantly reduced in the brains of animals injected systemically with IL-1b. 55 As IGF-1 induces neuronal proliferation and differentiation in the fetal rat brain, 56 it is possible that IL-1b-dependent decreases in IGF-1 might disrupt the normal growth and development of the fetal brain, leading to long-term behavioral alterations of relevance to schizophrenia.
Other downstream consequences of systemic cytokine induction during pregnancy include changes in circulating levels of glucocorticoid 57, 58 and thyroid hormones. 59, 60 Maternal glucocorticoid 61, 62 and thyroid 63 hormones can cross the blood placental barrier and are essential for normal fetal neurodevelopment. 64, 65 However, in humans, exposure of the fetus to excess glucocorticoids can have detrimental effects on fetal brain development 64, 66 and hypothyroidism during pregnancy is associated with impaired cognitive and motor function in children. 67, 68 Alternatively, the behavioral deficits observed in the adult offspring of rodents exposed to LPS during pregnancy could be the consequence of neurodevelopmental changes in the fetal brain resulting from LPS-dependent changes in the body temperature of the pregnant dam (i.e. fever). Indeed, it has been demonstrated that heat stress during gestation can result in neurodevelopmental abnormalities in both rodent 69, 70 and human brain. 71, 72 LPS-dependent fever is mediated by systemic cytokines including TNF-a, IL-1b and IL-6, 19 all of which increased significantly in the plasma of pregnant dams following administration of LPS in our study.
In conclusion, the findings of this study suggest that behavioral changes in the offspring of pregnant rats exposed to bacterial LPS during pregnancy are not mediated by the direct action of the endotoxin on the fetal brain, but are likely secondary to inflammatory responses (i.e. cytokine induction) in the maternal plasma and/or the placenta. Downstream consequences of these inflammatory responses, such as maternal fever, deficiencies in placental function, transfer of plasma/placental cytokines to the fetal circulation or altered expression of glucocorticoid and thyroid hormones, may contribute to altered fetal neurodevelopment following maternal infection during pregnancy.
